Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Lipella Pharmaceuticals Inc. (LIPO) had Return on Tangible Equity of -32.03% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.13M |
|
$-1.31M |
|
-- |
|
$0.13M |
|
$1.46M |
|
$-1.33M |
|
$0.02M |
|
$-1.31M |
|
$-1.31M |
|
$-1.31M |
|
$-1.31M |
|
$-1.31M |
|
$-1.31M |
|
$-1.33M |
|
$-1.33M |
|
2.06M |
|
2.06M |
|
$-0.64 |
|
$-0.64 |
|
| Balance Sheet Financials | |
$4.82M |
|
$0.01M |
|
$0.03M |
|
$4.86M |
|
$0.78M |
|
-- |
|
-- |
|
$0.78M |
|
$4.08M |
|
$4.08M |
|
$4.08M |
|
2.55M |
|
| Cash Flow Statement Financials | |
$-1.43M |
|
-- |
|
$3.47M |
|
$2.18M |
|
$4.22M |
|
$2.04M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1026.22% |
|
-1026.22% |
|
-- |
|
-1009.76% |
|
-1009.76% |
|
$-1.43M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
1.51 |
|
59.56 |
|
-32.03% |
|
|
Return on Tangible Equity |
-32.03% |
-26.91% |
|
-32.03% |
|
$1.60 |
|
$-0.69 |
|
$-0.69 |
|